Unknown OBSERVATIONAL NCT05451134

Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma

Sponsor: China National Center for Cardiovascular Diseases

Conditions Paraganglioma Pheochromocytoma

Updated 3 times since 2022 Last updated: Jul 9, 2022 Started: Jun 30, 2022 Primary completion: Jul 20, 2022 Completion: Jul 20, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05451134, this observational or N/A phase trial focuses on Paraganglioma and Pheochromocytoma and remains ongoing. Sponsored by China National Center for Cardiovascular Diseases, it has been updated 3 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Active Not Recruiting → Unknown
Sep 2022 — Jul 2024 [monthly]

Active Not Recruiting

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

China National Center for Cardiovascular Diseases
Peking Union Medical College Hospital

Data source: China National Center for Cardiovascular Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China